A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naive Patients with Advanced NSCLC

被引：3

作者：

Lisberg, A. ^{[1
]}

Hunt, J. ^{[1
]}

Reese, N. ^{[1
]}

Wang, T. ^{[1
]}

Coluzzi, P. ^{[1
]}

Spiegel, M. ^{[1
]}

Bornazyan, K. ^{[1
]}

Carroll, J. ^{[1
]}

Madrigal, J. ^{[1
]}

Ledezma, B. ^{[1
]}

Mendenhall, M. ^{[1
]}

Bui, J. ^{[1
]}

Lu, H. ^{[1
]}

Cummings, A. ^{[1
]}

Noor, Z. ^{[1
]}

Goldman, J. W. ^{[1
]}

Garon, E. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

EGFR; NSCLC; anti-PD-1; therapy;

D O I：

10.1016/j.jtho.2017.09.456

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA 02.07

引用

页码：S1805 / S1805

页数：1

共 50 条

[21] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
Otsuka, K.
Hata, A.
Kato, R.
Takeshita, J.
Okuda, C.
Kaji, R.
Masago, K.
Fujita, S.
Katakami, N.
ANNALS OF ONCOLOGY, 2014, 25
[22] Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Jung, Hyun Ae
Park, Sehhoon
Choi, Yoon-La
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Sun, Jong-Mu
CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2321 - 2328
[23] Biomarker analysis of a phase II trial of cabozantinib and erlotinib in patients (pts) with EGFR-mutant NSCLC with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance: A California Cancer Consortium Phase II Trial (NCI 9303).
Reckamp, Karen L.
Mack, Philip C.
Ruel, Nora
Frankel, Paul Henry
Gitlitz, Barbara J.
Li, Tianhong
Koczywas, Marianna
Gadgeel, Shirish M.
Cristea, Mihaela C.
Belani, Chandra Prakash
Newman, Edward M.
Gandara, David R.
Lara, Primo
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[24] A phase I/II study of TQ-B2450, a PD-L1 mAb, plus anlotinib in EGFR plus advanced NSCLC patients failed to prior EGFR TKI therapies.
Shi, Meiqi
Wang, Li
Yu, Shaorong
Yan, Fei
Peng, Wei
Feng, Jifeng
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] Clinical pharmacokinetics of simotinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC patients.
Han, Xiaohong
Li, Ning
Hu, Xingsheng
Song, Yuanyuan
Zhang, Yan
Shi, Yuankai
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[26] EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
Xu, Jianlin
Jin, Bo
Chu, Tianqing
Dong, Xue
Yang, Haitang
Zhang, Yanwei
Wu, Dan
Lou, Yuqing
Zhang, Xueyan
Wang, Huiming
Han, Baohui
LUNG CANCER, 2016, 96 : 87 - 92
[27] A single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance.
Bar, Jair
Botser, Dana
Navon, Rossie
Peled, Nir
Biran, Haim
Gal-Yam, Einav Nili
Ben-Arieh, Sayeh
Raskin, Stephen
Onn, Amir
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[28] Pembrolizumab in Paediatric Patients with Advanced Melanoma or A PD-L1-Positive (PD-L1+) Advanced, Relapsed, or Refractory Solid Tumour or Lymphoma: Phase 1/2 Keynote-051 Study
Geoerger, B.
Fox, E.
Pappo, A.
Yalon-Oren, M.
Marshall, V.
Vezina, C.
Pathiraja, K.
Diede, S. J.
Ebbinghaus, S.
Park, J. R.
PEDIATRIC BLOOD & CANCER, 2016, 63 : S195 - S195
[29] INHIBITION OF PEGFR IN PAIRED TUMOR BIOPSIES FROM TKI TREATMENT-NAIVE EGFR MUTANT NSCLC PATIENTS TREATED WITH GEFITINIB ± DURVALUMAB (ANTI-PD-L1)
Clarke, S.
Yeh, T.
Jacobs, V.
Angell, H.
Geradts, J.
Hou, J.
Karakunnel, J.
Barrett, C.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 53 - 53
[30] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
Stock-Martineau, Sophie
Shepherd, Frances A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797

← 1 2 3 4 5 →